Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 3/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135032 | 0.83 | CA12 (0.47) | TSHRRXRATTRCA12CA2 | |
| SCHEMBL20135706 | 0.80 | TSHR (0.47) | TDP1MEN1KMT2ATSHRRXRA | |
| SCHEMBL29688774 | 0.80 | TSHR (0.47) | TDP1MEN1KMT2ATSHRRXRA | |
| SCHEMBL20134939 | 0.79 | AKR1B1 (0.40) | KMT2ATSHRCA2 | |
| SCHEMBL20135221 | 0.79 | AKR1B1 (0.40) | KMT2ATSHRCA2 | |
| SCHEMBL20134941 | 0.79 | AKR1B1 (0.40) | KMT2ATSHRCA2 | |
| SCHEMBL29688586 | 0.77 | KDM4E (0.35) | GRM1KMT2ATSHRHSD17B10 | |
| SCHEMBL20135169 | 0.77 | KDM4E (0.35) | GRM1KMT2ATSHRHSD17B10 | |
| SCHEMBL20135280 | 0.74 | LCK (0.35) | TDP1MEN1KMT2ATSHRMYC | |
| SCHEMBL20135355 | 0.69 | AKR1B1 (0.36) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | GRM1 4141/4885TDP1 2301/4885MEN1 3735/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | GRM1 3929/4885TDP1 2384/4885MEN1 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.